OPK at a glance
OPKO HEALTH, INC. (OPK, SEC CIK 944809) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 27, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as July 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), OPKO HEALTH, INC. (OPK) reported revenue of $606.9 million (down 14.9% from FY2024) and a net loss of $225.7 million. Diluted EPS was -$0.30.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding OPKO HEALTH, INC. (OPK) shares worth $147.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by PAGANELLI JOHN A on March 20, 2026 of 10,000 shares at $1.14 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $606.9M
- −14.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $147.8M · +0 vs prior quarter
- Latest 8-K
- Aug 14, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material risk-factor changes from the 10-K; previously disclosed risks carried forward
- Liquidity risk: $451.716 million contractual obligations, including $246.854 million due thereafter under 2044 Royalty Financing
- Regulatory and legal risk: funding needs depend on clinical-trial outcomes, regulatory approvals, government investigations, and ITA litigation
- Operational risk: near-term cash requirements depend on Rayaldee success and partners’ Mazdutide launch
- Foreign-exchange risk: 33.3% of six-month revenue denominated outside USD, primarily Chilean Peso and Euro exposures
AI summary of the OPK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- OPKO issued $125 million of additional senior secured notes, increasing debt backed by future royalty cash flows
- Notes mature July 17, 2044, with interest at three-month SOFR plus 7.5%, subject to a 4.0% floor
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 operating and financial highlights announced for quarter ended June 30, 2026
- Management conference call scheduled for business update, results discussion, and financial guidance
Item EX-99.1: Item EX-99.1
- Q2 revenue $163.5M, up from $156.8M, while net loss narrowed to $8.4M from $148.4M
- Pharmaceuticals revenue rose to $89.0M, driven by $29.4M from Nicoya shares and stronger product sales
AI summaries of OPK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OPK
Don't miss the next OPK filing
- Alerts as it files. A push when OPK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OPK, by share count.
- Ask anything. An AI agent that reads every OPK filing and answers with sources.
OPK alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Rubin Steven D | F | Jul 24, 2026 | 53,266 | $1.22 |
| Logal Adam | F | Jul 24, 2026 | 53,266 | $1.22 |
| Yu Alice Lin-Tsing | A | Jun 18, 2026 | 30,000 | - |
| MEDEL ROGER MD | A | Jun 18, 2026 | 30,000 | - |
| PAGANELLI JOHN A | A | Jun 18, 2026 | 30,000 | - |
| UPPALURI SUBBARAO V | A | Jun 18, 2026 | 80,000 | - |
| Lachman Prem A | A | Jun 18, 2026 | 30,000 | - |
| PFENNIGER RICHARD C JR | A | Jun 18, 2026 | 60,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $713.1M | $606.9M |
| Gross Profit | $318.1M | $218.5M | $205.9M |
| Operating Income | - | -$152.1M | -$117.4M |
| Net Income | -$188.9M | -$53.2M | -$225.7M |
| Gross Margin | - | 30.6% | 33.9% |
| Op. Margin | - | -21.3% | -19.3% |
| Net Margin | - | -7.5% | -37.2% |
| Balance Sheet | |||
| Total Assets | $2.0B | $2.2B | $1.9B |
| Equity | - | $1.4B | $1.3B |
| ROE | - | -3.9% | -17.8% |
| Per Share | |||
| EPS | - | $-0.08 | $-0.30 |
| Cash Flow | |||
| Operating CF | -$28.2M | -$183.5M | -$178.5M |
Source: XBRL data in OPKO HEALTH, INC. (OPK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate OPK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $147.8M |
| Q1 2026 | 27 | $110.5M |
| Q4 2025 | 28 | $124.3M |
| Q3 2025 | 26 | $152.9M |
| Q2 2025 | 26 | $130.7M |
| Q1 2025 | 23 | $130.0M |
| Q4 2024 | 20 | $86.8M |
| Q3 2024 | 17 | $45.0M |
- State Street Corp+807.7K (+9%)
- Morgan Stanley+778.9K (+65%)
- BlackRock+746.7K (+2%)
- AQR Capital Management+475.8K (+62%)
- Vanguard Capital Management LLC+469.8K (+3%)
- Citadel Advisors LLC−658.6K (-32%)
- Goldman Sachs Group−639.5K (-8%)
- Bank of America Corp−346.1K (-30%)
- JPMorgan Chase & Co−340.2K (-67%)
- Dimensional Fund Advisors−292.3K (-19%)
- Millennium Management+72.3K
- U.S. Bancorp+1.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 194 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OPK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| SC 13D | Aug 7, 2026 | - | - | |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 10-Q | Jul 27, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 10-Q | Apr 28, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 20, 2026 | - | - | - |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Jul 31, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 1, 2025 | Mar 31, 2025 | - | |
| SC 13G | Apr 2, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OPK SEC filings: frequently asked questions
Which institutions hold OPK stock?
As of June 30, 2026, the largest OPKO HEALTH, INC. (OPK) holders among the 13F filers tracked by SignalX were BlackRock ($55.5 million), Vanguard Capital Management LLC ($22.5 million), Vanguard Portfolio Management LLC ($22.4 million), State Street Corp ($15.5 million), Goldman Sachs Group ($10.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OPK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), OPKO HEALTH, INC. (OPK) reported revenue of $606.9 million (down 14.9% from FY2024) and a net loss of $225.7 million. Diluted EPS was -$0.30. The figures come from the XBRL data in the 10-K.
What did OPK report in its latest 8-K?
OPKO HEALTH, INC. (OPK) filed an 8-K on August 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). OPKO issued $125 million of additional senior secured notes, increasing debt backed by future royalty cash flows.
What are the latest OPK SEC filings?
OPKO HEALTH, INC. (OPK) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 27, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on July 28, 2026.
What is OPK's SEC CIK number?
OPKO HEALTH, INC. (OPK)'s SEC Central Index Key (CIK) is 944809. EDGAR lists every OPK filing under that number.
Ask anything about OPK
The research agent reads OPK's filings, financials, insider trades and 13F holders, then answers with sources.